The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals
Major ADC Projects Underway
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
You may also be interested in...
Korean biopharma companies and the government are making diverse efforts to collaborate and seek growth to overcome limited resources and capital, as well as a tough investment environment.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
Sandoz is eyeing development of up to three subcutaneous formulation biosimilars, which offer greater benefits to both patients and healthcare providers, via a technology agreement with Korean firm Alteogen.